

10/088319

JC10 Received 13 MAR 2002

EXPRESS MAIL CERTIFICATE

3/13/02 EV039139399US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print)

Signature

Customer No.:



Docket No.: 5983/1G123-US2

07278

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mary K. CROW; Yixin LI

Serial No.: t/b/a

Confirmation No.:

Filed: Concurrently Herewith

For: ALTERED NUCLEOTIDE SEQUENCE IN CD40 LIGAND PROMOTER

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed within three months of the filing of the application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

10/088319

JC10 Rec'd PG/PFO 13 MAR 2002


It is believed that no fee is due. However, if the Commissioner

determines that a fee is due, the Commissioner is hereby authorized to charge the above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: March 13, 2002



Howard M. Frankfort, Ph.D.

Registration No. 32,613

Agent for Applicant(s)

DARBY & DARBY
805 Third Avenue
New York, NY 10022
(212) 527-7700

10/088319

JC10 Rec'd PCT/PTO 13 MAR 2002

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

SHEET 1 OF 1
(REV. 7-80)**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 5983/1G325US2 SERIAL NO: t/b/a
APPLICANT: Mary K. CROW FILING DATE: Concurrently Herewith
CONFIRMATION NO:

U.S. PATENT DOCUMENTS

*EXAMINER	DOCUMENT					
<u>INITIALS</u>	<u>NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>

FOREIGN PATENT DOCUMENTS

*EXAMINER	DOCUMENT				TRANSLATION		
<u>INITIALS</u>	<u>NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>YES</u>	<u>NO</u>

OTHER REFERENCES**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**

*EXAMINER
INITIALS

1. SCHUBERT et al., "The Human gp39 Promoter", *J. Biol. Chem.*, Vol. 270, No. 50, 15 December 1995, p.

29624-29627

2. BERNER et al., "Increased Expression of CD40 ligand (CD154) on CD4+T cells as a marker of disease activity in rheumatoid arthritis", *Rheum Dis*, Vol. 59, 2 November 1999, p.190-195

EXAMINER: _____

DATE CONSIDERED: _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.